Para munthu wali na kansa ya prostate wakuŵa na suzgo la kupulika mazgu agho ghakuyowoya vya umo thupi lake likugwilira ntchito.
Khansa ya prostate ni nthenda iyo yikupangika mu maselo gha prostate gland, agho ghali nga ni mtedza ndipo ghakusangika kusi kwa chikhodzodzo cha ŵanalume.
Nthumbo iyi yikupanga maji agho ghakovwira kuti wanalume watore wanakazi.
Nangauli ŵanthu ŵakumanya makora yayi ico cikupangiska kansa ya prostate, kweni pali vinthu vinandi ivyo vikupangiska kuti munthu wasuzgike comene na kansa iyi.
Vinyake mwa vinthu ivi ni msinkhu, mbumba, mtundu, na majini ghanyake agho munthu wali nagho.
Kansa ya prostate yikusuzga chomene ŵanalume ŵalara msinkhu.
Kweniso ŵanalume awo ŵabali ŵawo ŵali na kansa ya mu chibabiro ŵakusuzgika chomene.
Para munthu wali na kansa ya prostate, maselo ghakuŵa na nkhongono ndipo ghakupambana.
Ivi vingacitika cifukwa ca kusintha kwa majini agho ghakupangiska kuti tumigelo tunyake tukure comene panji kuti majini agho ghakukanizga kukura kwa tumigelo ghatondeke kugwira nchito.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
['Kujivikilira: vya cipatala']
['Webusayiti iyi yili na cilato ca kusambizga waka ŵanthu, kuti njakupeleka ulongozgi wa vyacipatala yayi.']
['Manyani kuti makina agho ghakuzgora mafumbo agha ghakutondeka kulongosora makora vinthu nga ni unandi wa ŵanthu awo ŵali na nthenda yinyake.']
['Nyengo zose mukwenera kufumba dankha dokotala panji munthu munyake wakumanya vya munkhwala uyo wangamovwirani pa suzgo linu. Lekani kuzerezga ulongozgi wa dokotala panji kuchedwa kupenja ulongozgi uwu chifukwa cha ivyo mwaŵazga pa webusayiti iyi.']
['Copyright: Copyright']
['The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) imapereka mwayi kwa eni ake omwe amakhulupirira kuti zomwe zikuwoneka pa intaneti zikuphwanya ufulu wawo pansi pa malamulo a US copyright. ']
['Para mwalemba kalata, mukwenera kutuma pa adiresi ya e-mail (wonani pa "Contact").']
['Dango la DMCA likukhumba kuti para mwalemba kuti munthu munyake wananga vinthu ivyo muli navyo, mulembepo vinthu ivi: (1) ivyo vyalembeka, (2) ivyo vyalembeka, na ivyo vingatovwira kusanga ivyo vyalembeka, (3) umo tingamumanyira, na adiresi yake, nambara yake ya foni, na adiresi yake ya imelo, (4) usange mukugomezga kuti ivyo mwalemba ni vyambura kuzomerezgeka na mweneko wa vinthu, panji na munthu uyo wakumugwiliskira ntchito, panji dango lililose.']
['(5) mukalemba chikalata chakuyowoya kuti ivyo mwalemba ni vyaunenesko kweniso kuti muli na mazaza ghakuvikilira wanangwa uwo ŵanthu ŵakuti wanangika.']
['Ndipo (6) munthu uyo wali na wanangwa wa kulemba panji munthu uyo wali na mazaza ghakuchitira vinthu vinyake mu zina la mwenecho wa wanangwa uwu. ']
['Chonde titumizireni imelo ndi funso / lingaliro lililonse.']
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
